Latest News

Winter 2018 Compass Now Available Online

February 9, 2018
Posted in , ,

The winter 2018 issue of Compass is now available online. This issue covers Cure SMA’s community survey, and reviews how data is used to improve research, care and coverage in […]

Read More ›

Advisory Committee on Heritable Disorders in Newborns and Children Recommends Nationwide Newborn Screening for Spinal Muscular Atrophy

February 8, 2018
Posted in , ,

The Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) today recommended that newborn screening for spinal muscular atrophy be implemented nationwide. This decision is an important step toward […]

Read More ›

Utah Becomes First State to Implement Permanent Screening for SMA

February 6, 2018
Posted in , ,

The Utah Department of Public Health has announced that, effective immediately, all newborns born in the state will be screened for spinal muscular atrophy. This announcement makes Utah the first […]

Read More ›

Federal Committee to Vote on Spinal Muscular Atrophy Newborn Screening on Thursday

February 2, 2018
Posted in , ,

On Thursday, February 8, the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC), a federal committee that oversees newborn screening, will vote on whether to recommend newborn screening […]

Read More ›

Preliminary Data from FIREFISH Trial in Type 1 SMA Infants Presented at the International Scientific Congress on Spinal Muscular Atrophy

January 30, 2018
Posted in , ,

PTC Therapeutics, Inc. recently announced the presentation of early interim data from Part 1, the dose-finding portion of the FIREFISH study. FIREFISH is a two-part seamless, open-label, multi-center study to […]

Read More ›

AveXis Releases Community Statement on Expanded Clinical Trials

January 26, 2018
Posted in , ,

AveXis has provided the following community statement on AVXS-101. Dear SMA Community, At AveXis, the gene replacement therapy company developing a new approach to treat SMA known as AVXS-101, we […]

Read More ›
Scroll to Top